Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vaxart, Inc. (VXRT)

1.11   0.03 (2.78%) 01-27 16:00
Open: 1.07 Pre. Close: 1.08
High: 1.13 Low: 1.065
Volume: 1,389,188 Market Cap: 146(M)

Technical analysis

as of: 2023-01-27 4:49:13 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.47     One year: 1.71
Support: Support1: 0.93    Support2: 0.73
Resistance: Resistance1: 1.25    Resistance2: 1.47
Pivot: 1.09
Moving Average: MA(5): 1.09     MA(20): 1.06
MA(100): 1.55     MA(250): 3.06
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 52.9     %D(3): 52.3
RSI: RSI(14): 51.9
52-week: High: 5.42  Low: 0.73
Average Vol(K): 3-Month: 3,423 (K)  10-Days: 1,785 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VXRT ] has closed below upper band by 43.6%. Bollinger Bands are 54.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.13 - 1.14 1.14 - 1.15
Low: 1.05 - 1.06 1.06 - 1.07
Close: 1.1 - 1.11 1.11 - 1.12

Company Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Headline News

Fri, 27 Jan 2023
Should Biotechnology Stock Vaxart Inc (VXRT) Be in Your Portfolio Friday? - InvestorsObserver

Fri, 27 Jan 2023
Vaxart Inc. (NASDAQ:VXRT): -402.78% Off High, Can It Comeback? - Marketing Sentinel

Tue, 24 Jan 2023
Looking Closely at the Growth Curve for Vaxart Inc. (VXRT) - The News Heater

Fri, 20 Jan 2023
How Will the Market React to Vaxart Inc (VXRT) Stock Getting a Neutral Rating - InvestorsObserver

Wed, 11 Jan 2023
AMC, BNGO and VXRT are among pre market gainers - Seeking Alpha

Tue, 10 Jan 2023
Is Vaxart Inc (VXRT) Stock Worth a Buy Tuesday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 131 (M)
% Held by Insiders 1.303e+008 (%)
% Held by Institutions 0.8 (%)
Shares Short 24,640 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -9.955e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -65
Return on Assets (ttm) 823.2
Return on Equity (ttm) -31.5
Qtrly Rev. Growth 159000
Gross Profit (p.s.) 0
Sales Per Share -84.12
EBITDA (p.s.) -6.29737e+007
Qtrly Earnings Growth -0.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -81 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0.88

Stock Dividends

Dividend 0
Forward Dividend 2.371e+007
Dividend Yield 0%
Dividend Pay Date 2023-12-19
Ex-Dividend Date 2012-11-08
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.